Expression of Bcl-2 and p53 in the colorectal adenoma-carcinoma sequence

被引:22
作者
Hao, XP
Ilyas, M
Talbot, IC
机构
[1] ST MARKS HOSP,ACAD DEPT PATHOL,IMPERIAL CANC RES FUND,COLORECTAL CANC UNIT,HARROW HA1 3UJ,MIDDX,ENGLAND
[2] JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,INST MOL MED,CANC GENET & IMMUNOL LAB,OXFORD OX3 9DU,ENGLAND
关键词
Bcl-2; p53; apoptosis; colorectum; carcinogenesis;
D O I
10.1159/000164115
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To evaluate the respective roles of Bcl-2 and p53 during colorectal tumour growth, 73 sporadic adenomas and 54 carcinomas arising in adenomas were studied by immunohistochemistry. Bcl-2 protein was expressed in 72 of 73 (98.6%) adenomas and in 25 of 54 (46.3%) carcinomas, whereas p53 protein expression was found in 18 of 73 (24.6%) adenomas and 23 of 54 (42.6%) carcinomas. Bcl-2 expression was related to the size and increasing severity of dysplasia (p < 0.05), while p53 expression was associated with the degree of dysplasia, but not with size (p < 0.025 and p > 0.10, respectively). Bcl-2 expression in carcinomas arising in adenomas was significantly reduced when compared with the associated adenoma (p < 0.005). However, there was no such difference in p53 expression between carcinomas and associated adenomas. Interestingly, there were inverse correlations between p53 and Bcl-2 expression in both adenomas and carcinomas (p < 0.05 and p < 0.005, respectively). We conclude that increased expression of Bcl-2 in adenomas may imply increasing protection against apoptosis during the progression from mild to severe dysplasia. Reduced expression of Bcl-2 may be due to downregulation by mutant p53 and may mark the point of transition from adenoma to carcinoma.
引用
收藏
页码:140 / 145
页数:6
相关论文
共 38 条
[1]  
Ahnen DJ, 1996, AM J GASTROENTEROL, V91, P3
[2]  
AKAO Y, 1994, CANCER RES, V54, P2468
[3]   CLONING THE CHROMOSOMAL BREAKPOINT OF T(14-18) HUMAN LYMPHOMAS - CLUSTERING AROUND JH ON CHROMOSOME-14 AND NEAR A TRANSCRIPTIONAL UNIT ON 18 [J].
BAKHSHI, A ;
JENSEN, JP ;
GOLDMAN, P ;
WRIGHT, JJ ;
MCBRIDE, OW ;
EPSTEIN, AL ;
KORSMEYER, SJ .
CELL, 1985, 41 (03) :899-906
[4]   BCL-2 ONCOPROTEIN IN COLORECTAL HYPERPLASTIC POLYPS, ADENOMAS, AND ADENOCARCINOMAS [J].
BOSARI, S ;
MONEGHINI, L ;
GRAZIANI, D ;
LEE, AKC ;
MURRAY, JJ ;
COGGI, G ;
VIALE, G .
HUMAN PATHOLOGY, 1995, 26 (05) :534-540
[5]  
BRONNER MP, 1995, AM J PATHOL, V146, P20
[6]   NUCLEAR AND CYTOPLASMIC BCL-2 EXPRESSION IN ENDOMETRIAL HYPERPLASIA AND ADENOCARCINOMA [J].
CHAN, WK ;
MOLE, MM ;
LEVISON, DA ;
BALL, RY ;
LU, QL ;
PATEL, K ;
HANBY, AM .
JOURNAL OF PATHOLOGY, 1995, 177 (03) :241-&
[7]   THE BCL-2 CANDIDATE PROTO-ONCOGENE PRODUCT IS A 24-KILODALTON INTEGRAL-MEMBRANE PROTEIN HIGHLY EXPRESSED IN LYMPHOID-CELL LINES AND LYMPHOMAS CARRYING THE T(14,18) TRANSLOCATION [J].
CHENLEVY, Z ;
NOURSE, J ;
CLEARY, ML .
MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (02) :701-710
[9]   A P53-DEPENDENT MOUSE SPINDLE CHECKPOINT [J].
CROSS, SM ;
SANCHEZ, CA ;
MORGAN, CA ;
SCHIMKE, MK ;
RAMEL, S ;
IDZERDA, RL ;
RASKIND, WH ;
REID, BJ .
SCIENCE, 1995, 267 (5202) :1353-1356
[10]  
DOGLIONI C, 1994, VIRCHOWS ARCH, V424, P47